Cenix BioScience GmbH And The Instituto de Medicina Molecular Initiate First Genome-Scale RNAi Screen For Novel Malaria Genes
10/19/2005 5:09:23 PM
DRESDEN, Germany & LISBOA, Portugal--(BUSINESS WIRE)--June 29, 2005--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, and the Instituto de Medicina Molecular (IMM, Lisboa) have initiated a research collaboration to identify human genes required for the malaria infection process, using systematic genome-scale RNAi screening. The identified genes will represent excellent candidates for the development of novel anti-malarial therapeutics.
comments powered by